Benzodiazepines remain widely used for the treatment of anxiety disorders despite prominent, often limiting side effects including sedation, muscle relaxation, and ataxia. A compound producing a robust anxiolytic action comparable to benzodiazepines, but lacking these limiting side effects at therapeutic doses (an anxioselective agent), would represent an important advance in the treatment of generalized anxiety disorder, and perhaps other anxiety disorders. Here we report that the pyrazolo[1,5-a]-pyrimidine, ocinaplon, exhibits an anxioselective profile in both preclinical procedures and in patients with generalized anxiety disorder, the most common of the anxiety disorders. In rats, ocinaplon produces significant muscle relaxation, ataxia, and sedation only at doses >25-fold higher than the minimum effective dose (3.1 mg͞kg) in the Vogel ''conflict'' test. This anticonflict effect is blocked by flumazenil (Ro 15-1788), indicating that like benzodiazepines, ocinaplon produces an anxiolytic action through allosteric modulation of GABA A receptors. Nonetheless, in eight recombinant GABAA receptor isoforms expressed in Xenopus oocytes, the potency and efficacy of ocinaplon to potentiate GABA responses varied with subunit composition not only in an absolute sense, but also relative to the prototypical benzodiazepine, diazepam. In a double blind, placebo controlled clinical trial, a 2-week regimen of ocinaplon (total daily dose of 180 -240 mg) produced statistically significant reductions in the Hamilton rating scale for anxiety scores. In this study, the incidence of benzodiazepine-like side effects (e.g., sedation, dizziness) in ocinaplon-treated patients did not differ from placebo. These findings indicate that ocinaplon represents a unique approach both for the treatment and understanding of anxiety disorders.
B
enzodiazepines remain widely used for the treatment of anxiety disorders (1, 2) despite significant limiting side effects including sedation, muscle relaxation, and ataxia. This spectrum of pharmacological actions is produced by augmenting the actions of the inhibitory neurotransmitter GABA through an allosteric modulation of GABA A receptors (3, 4) , a family of heteropentameric, ligand-gated ion channels (5) . Although there are at least seven subunit classes, the majority of GABA A receptors are composed of ␣-, ␤-, and ␥-subunits (6), with multiple subtypes of each that can assemble to form GABA-gated ion channels (5, 7) . This subunit repertoire allows for remarkable receptor diversity, and Ͼ12 distinct GABA A receptor isoforms may be present in the mammalian nervous system (8) .
Benzodiazepines bind to and act upon a subset of GABA A receptors containing ␤-and ␥-subunits in combination with ␣1-, ␣2-, ␣3-, or ␣5-subunits. The identification of novel molecules acting at the benzodiazepine recognition site of the GABA A receptor began Ͼ25 years ago (9, 10) , and remains an area of intense interest (2, 5, 11, 12) . The impetus for identifying such molecules was the discovery that the triazolopyridazine, CL 218,872 (9, 10) , exhibited selectivity for ''Type I'' benzodiazepine receptors (subsequently identified as GABA A receptors containing an ␣1-subunit; refs. 5 and 13) and a low efficacy relative to benzodiazepines in potentiating GABA-gated chloride currents (14, 15) . CL 218,872 produced anxiolytic-like effects in animal models at doses substantially lower than those producing benzodiazepine-like side effects (e.g., sedation, ataxia, muscle relaxation) (16) . A compound exhibiting this ''anxioselective'' profile in humans would represent a significant advance in the treatment and understanding of anxiety disorders.
A number of compounds have been identified that exhibit GABA A receptor subtype selectivity and͞or lower efficacy than benzodiazepines to enhance GABA-stimulated chloride currents (reviewed in ref. 2) . Some compounds, such as bretazenil and abecarnil, exhibit an anxioselective profile in animals (17, 18) , but data from clinical trials do not support the anxioselectivity predicted from preclinical results (19, 20) . We now report that ocinaplon (DOV 273,547; 2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]-pyrimidin-3-yl]methanone) fulfills both preclinical and clinical criteria for an anxioselective agent.
Methods
''Thirsty Rat'' Conflict Test. The procedure used in this study was essentially as originally described by Vogel et al. (21) . The effects of drugs or vehicle (n Ն 8 animals per dose) were evaluated 1 h after oral administration. See Supporting Text, which is published as supporting information on the PNAS web site, for further details.
was evaluated (22) . The ED 50 was that dose causing 50% of the rats to fall. ED 50 values were calculated by the probit analysis method of Finney (23) .
Squirrel Monkey Conflict Procedure. The effects of ocinaplon, diazepam, and vehicle were evaluated in a conflict procedure (22, 24) using adult, male squirrel monkeys (Saimiri sciureus). Drugs or vehicle were administered by gavage 60 min before placing the animals in the operant conditioning chamber. The mean reinforced responses, mean conflict responses, and mean conflict response failures were calculated for each dosage level. Significant differences between drug responding and control level (obtained on the day before treatment) were determined by using a paired t test. See Supporting Text for further details.
Clinical Study in Generalized Anxiety Disorder. Twenty centers in Germany received Ethics Committee approval to participate in this study, with 15 centers enrolling patients. The study was performed in accordance with the declaration of Helsinki, Good Clinical Practice on Medicinal Products in the European Community, Food and Drug Administration Good Clinical Practice Regulations, and International Harmonization Good Clinical Practice Guidelines. Study-related procedures were not initiated until a subject had given written informed consent on an Institutional Review Boardapproved consent form. Eligible outpatients Ն18 years of age who met the DSM-IV criteria for general anxiety disorder (GAD), had sufficient initial symptom severity to require treatment [total score on the Hamilton Rating Scale for Anxiety (HAM-A) Ն 22], and did not have coexisting depressive symptoms [total score on the Hamilton Rating Scale for Depression (HAM-D) Յ 15] were included in a placebo run-in period (single-blind, 1-week dosing). Those individuals whose HAM-A scores did not decrease by Ͼ10% during the run-in period were enrolled in a 14-day, double-blind treatment period and randomized to one of three treatment groups. In addition to the principal efficacy measure, change in the HAM-A (25), secondary measures of efficacy included the clinical global impression scale, and the patient's self-rating scale for generalized anxiety (26) . Repeated weekly assessments of symptom severity over time served as the dependent variable in the analyses for efficacy. Adverse experiences were evaluated at baseline (i.e., end of screening͞placebo run-in period) and at the beginning of every week thereafter. Each nonlaboratory adverse experience reported by the patients was rated for its severity and for its relationship with the study drug. Vital signs were evaluated by monitoring sitting blood pressure, respiratory rate, temperature, and pulse rate. Screening and safety analysis consisted of blood chemistry and liver function tests in conjunction with urinalysis and hematologic testing (complete blood count). 
Evaluation of GABA-Gated Currents in Recombinant Human GABAA
Receptors Expressed in Xenopus Oocytes. cRNAs encoding GABA A receptor ␣1, 2-, 3-, or 5-, ␤2, and ␥2-or 3-subunits were microinjected into Xenopus laevis oocytes. Forty-eight hours later, the effects of ocinaplon and diazepam were measured on GABA-gated inward currents using a Warner two-electrode voltage clamp amplifier in voltage clamp mode as described (see ref. 28 and Supporting Text for further details).
Animals. Studies in both rats and monkeys were conducted at Lederle Laboratories (Pearl River, NY). Protocols were approved by the Animal Care and Use Committee consistent with National Institutes of Health guidelines. Studies in X. laevis frogs were approved by the Animal Care and Use Committee, Boston University School of Medicine. Male CD rats (Charles River Breeding Laboratories) weighing 120-220 g were used in these experiments. Adult, male squirrel monkeys (S. sciureus) were obtained from a local colony. Female, oocyte-positive X. laevis frogs were purchased from Xenopus One (Ann Arbor, MI) or Nasco (Fort Atkinson, WI).
Drugs. Ocinaplon was manufactured by ACRAF SpA (Aprilia, Italy). Diazepam, flumazenil, and other reagents were obtained from Sigma͞Research Biochemicals. Drugs were suspended in 0.5% methylcellulose containing 0.1% Tween 80.
Results

Preclinical Studies in Rodents and
Primates. The ability of a drug to increase punished responding in ''conflict'' procedures is highly predictive of an antianxiety effect in humans (21, 22, 29) . Ocinaplon produced a dose-related increase in punished responding in a ''thirsty rat'' conflict procedure (21) with a potency and efficacy comparable to the prototypic benzodiazepine, diazepam (Fig. 1) . The minimum effective dose for each drug was 3.1 mg͞kg when administered orally 1 h before testing. The ability of flumazenil (Ro 15-1788) to antagonize the anticonflict action of ocinaplon ( Fig. 1) indicates that, like benzodiazepines (30) , this effect is mediated by GABA A receptors. Furthermore, ocinaplon was as potent and effective as diazepam in reducing pentylenetetrazole-induced convulsions [ED 50 values of 9.6 (95% CI; range, 7.9-12.1) mg͞kg and 7.5 (95% CI; range, 5.3-10.6) mg͞kg orally, respectively], another preclinical test that is highly predictive of an antianxiety effect in humans (22) .
Ocinaplon produced performance deficits comparable to diazepam in the motor activity, rod-walking, and inclined screen tests (Fig. 2) that are considered predictive of side effects (sedation, ataxia, and muscle relaxation, respectively) typically associated with benzodiazepines (22) . However, ocinaplon was 5-to 10-fold less potent than diazepam in disrupting performance in these tests, in contrast to its potency in the thirsty rat conflict and antipentylenetetrazole tests. This differential potency of ocinaplon in rodents is consistent with the profile of an ''anxioselective'' agent.
Ocinaplon produced a similar anxioselective profile in nonhuman primates. Squirrel monkeys were trained to bar press under conditions of both reward and punishment in a conflict procedure that is sensitive to clinically effective anxiolytics (22, 24) . The minimum effective dose (MED) for ocinaplon to increase punished responding was 4 mg͞kg orally; a significant increase in punished responding was maintained until a dose of 64 mg͞kg. At a dose of 128 mg͞kg, both punished and food reinforced responding were decreased (Fig. 3) . The MED for diazepam to increase punished responding in this procedure was 0.5 mg͞kg. However, this anticonflict effect was no longer apparent at doses Ն2 mg͞kg, pre- sumably because of disruption of motor activity that also significantly reduced responding under a reinforcing (nonpunishment) schedule at a dose of 4 mg͞kg (Fig. 3) .
Ocinaplon in Patients with GAD. Based on these preclinical results, we initiated a multicenter, double-blind, placebo-controlled safety and efficacy study of ocinaplon in GAD. Eligible patients were enrolled in a 14-day double-blind treatment period and randomized to one of three treatment groups: placebo (n ϭ 42), 60 mg of ocinaplon three times a day (TID) (n ϭ 43), or 120 mg of ocinaplon twice daily (BID) (n ϭ 42). The principal efficacy measure was change in the HAM-A score at the end of the 2-week study.
Hierarchical linear modeling analysis of HAM-A scores obtained from the intent-to-treat (ITT) population comprising all randomized subjects (including patients who did not complete the trial) yielded a significant interaction between time and treatment (t ϭ 2.6, P ϭ 0.011) for the global contrast between ocinaplon and placebo. Patients assigned to placebo displayed a mean reduction in HAM-A scores of 9.7 Ϯ 1.4 (standard error) points (P ϭ 0.001) after 2 weeks, whereas the reduction in total HAM-A scores in patients assigned to the 60-mg ocinaplon TID and 120-mg ocinaplon BID arms were 14.1 Ϯ 1.9 and 15.3 Ϯ 1.9 points, respectively. Analyses of the individual treatment group contrasts in the ITT population for the 2-week data demonstrated that 120-mg ocinaplon BID elicited a significantly greater reduction in symptom severity compared to placebo (t ϭ 2.34, P ϭ 0.02). The difference between 60-mg ocinaplon TID and placebo approached statistical significance (t ϭ 1.89, P ϭ 0.06). Investigation of the effect size estimates indicated that the two doses were essentially identical in efficacy (with slight numerical advantage for 120-mg ocinaplon BID compared to 60-mg ocinaplon TID). An analysis of the set of patients completing the study with no protocol deviation (n ϭ 32, 35, and 31 for placebo, 180 mg of ocinaplon, and 240 mg of ocinaplon, respectively) yielded results (Fig. 4) essentially identical to those found in the ITT sample. A statistically significant difference in HAM-A scores for the global contrast between ocinaplon and placebo was observed as early as 1 week (P ϭ 0.022) after the start of dosing. Statistically significant dose ϫ time interactions were also observed for each individual dose of ocinaplon (t ϭ 1.7, df ϭ 66, P ϭ 0.09 for 180 mg͞day ocinaplon vs. placebo; t ϭ 3.1, df ϭ 62, P ϭ 0.003 for 240 mg͞day ocinaplon) compared to placebo. The reductions in HAM-A scores produced by ocinaplon were paralleled by changes in both the clinical global impression and selfrating scale measures (data not shown).
There were no treatment-emergent, serious adverse events in this trial. The number of patients in each group with at least one treatment emergent adverse event in the trial was relatively low (Table 1) , and the proportion of patients with treatment emergent adverse events was comparable among treatment groups (placebo, 9.5%; 240 mg of ocinaplon, 9.5%; 180 mg of ocinaplon, 11.6%; P ϭ 1.0, Fisher's exact test). No clinically significant, treatmentemergent laboratory abnormalities were detected in the study population. In general, the overall side-effect profile was unremarkable across the entire study population. Of particular note was an absence of significant findings or trends for the central nervous system and other effects normally associated with benzodiazepines such as sedation and dizziness ( (Fig. 1) . Ocinaplon was Ϸ3-fold more potent in inhibiting [ 3 H]flunitrazepam binding to rat cere- Patients reporting individual AEs may not add up to the number of patients within a SOC because a subject may have reported more than one AE with in a SOC term. MeDRA, medical dictionary regulatory applications; NOS, not otherwise specified. *No significant difference among treatments in proportion of patients with AEs.
. These radioligand-binding data indicate that compared to diazepam, the prototypic benzodiazepine, ocinaplon is a lowaffinity ligand at GABA A receptors that exhibits a modest selectivity for GABA A1 receptors (receptors containing ␣1-subunits; ref. 5) , because this subunit is enriched in cerebellum compared to cortex (6, 33, 34) .
To determine how subunit composition influences the molecular actions of ocinaplon at GABA A receptors, cRNAs corresponding to specific combinations of ␣1, 2-, 3-, or 5-, ␤2, and ␥2-or 3-subunits were subcloned and microinjected into X. laevis oocytes. Forty-eight hours later, the effects of ocinaplon and diazepam were measured on GABA-gated inward currents in the voltage clamp mode (28) . Both the potency and efficacy (that is, the maximal effect) of diazepam to potentiate GABA-stimulated chloride currents varied with subunit composition (Fig. 5 and Table 2 ). Likewise, the potency and efficacy of ocinaplon varied with subunit composition (see Fig. 5 and Table 2 ), not only in an absolute sense but also relative to diazepam. Thus, ocinaplon increased GABA-stimulated chloride currents with efficacies ranging from Ϸ25% to 85% relative to diazepam, and potencies 5-to 35-fold lower than diazepam across these eight recombinant receptor isoforms. The greatest relative potentiation of GABA-stimulated currents was produced in receptors containing the ␣1-subunit. In those cells containing the ␣1␤2␥2 isoform where ocinaplon displayed the greatest relative efficacy, diazepam was approximately eight times more potent than ocinaplon in its ability to potentiate GABAstimulated currents (see Table 2 ), a relative potency comparable to that seen in the squirrel monkey conflict procedure (Fig. 3) . The substitution of a ␥3-subunit in this ␣1-containing complex reduced the relative efficacy of ocincaplon with only a small increase in relative potency. Similar substitution of a ␥3-subunit in the ␣2-, ␣3-, and ␣5-containing complexes produced larger increases in the relative potency of ocinaplon while decreasing its relative efficacy (Table 2) . Ocinaplon may thus be viewed as a partial positive modulator at ␣2-, ␣3-, and ␣5-containing receptors because its efficacy was substantially lower than diazepam at these receptor isoforms ( Table 2) .
Discussion
Ocinaplon is anxiolytic in rodents and primates, including humans, with a magnitude of effect comparable to benzodiazepines. Thus, in ''conflict'' procedures that are predictive of anxiolytic activity (22) , ocinaplon produced a maximum response comparable to the prototypic benzodiazepine diazepam (Figs. 1 and 3) . In GAD patients, the difference from placebo in the HAM-A score (4.4-5.6 points) in both ocinaplon dose groups (180-and 240-mg total daily dose) after 2 weeks of treatment (Fig. 4) was comparable to the difference (5.1 points) recently reported after 4 weeks of treatment with the benzodiazepine, lorazepam (6-mg total daily dose) (32) . However, in contrast to the side effect profile typically produced by anxiolytic doses of benzodiazepines (e.g., a high incidence of patients experiencing somnolence, dizziness, and incoordination) (32), the incidence of adverse events with ocinaplon was not different from placebo (Table 1) . Additional multicenter studies of longer duration are in progress to confirm both the efficacy of ocinaplon in reducing the symptoms of GAD and its apparent anxioselective profile.
Previously published results using genetically modified ''knockin'' mice have emphasized ␣2-containing receptor isoforms as critical for mediating the anxiolytic effects of benzodiazepines, and ␣1-containing isoforms as important for mediating the sedative effects (35, 36) . Thus, at face value, the present results are at variance with these previously reported data because ocinaplon was most potent and efficacious, both in an absolute sense and relative to diazepam, in receptors containing ␣1-subunits. Several different interpretations might explain this apparent inconsistency.
First, it is possible that ocinaplon and benzodiazepines act on different GABA A receptor subtypes such that ocinaplon produces its anxiolytic effects through actions on ␣1-containing complexes, whereas benzodiazepines and perhaps other structural classes of compounds (11, 12) produce anxiolytic effects through actions on ␣2-containing (GABA A2 ) receptors. This hypothesis is presently 5 . Potentiation of GABA-gated currents by ocinaplon and diazepam in recombinant rat GABA A receptors expressed in Xenopus oocytes. Potentiation was determined by using an EC 10 concentration of GABA. Curves were fitted by using nonlinear regression analysis and represent the mean values obtained from at least five oocytes harvested from at least two batches. Open circles, diazepam; filled circles, ocinaplon.
under investigation in selectively bred ''knock-in'' mice expressing either GABA A1 or GABA A2 receptors that are insensitive to benzodiazepines (35) (36) (37) . Second, it is possible that only partial activation of ␣2-containing GABA A receptors by ocinaplon is sufficient to produce a full anxiolytic effect. The low efficacy of L-838,417 (which exhibits an anxioselective profile in animals) relative to benzodiazepines at ␣ 2 -containing receptors is consistent with this hypothesis (12, 36) . However, this hypothesis does not adequately explain the anxioselective property of ocinaplon, given its potency and efficacy at ␣ 1 -containing receptors, which are presumed to mediate the sedative effects of benzodiazepines. A variation of this hypothesis posits that anxiolysis requires that a compound produce only partial activation, whereas ''side effects'' require full activation of GABA A receptors relative to a benzodiazepine. However, this hypothesis may also be viewed as flawed because ocinaplon, despite its partial agonist profile at ␣2-, ␣3-, and ␣5-containing receptors (Fig. 5 and Table 2 ), produces sedation, muscle relaxation, and ataxia, albeit at doses more than one order of magnitude higher than those producing an anxiolytic effect. Rather, a combination of high relative potency and high relative efficacy at certain receptor subtypes would seem to more parsimoniously explain its anxioselective properties. Finally, although studies using knock-in mice indicate that GABA A1 receptors contribute to the sedative and anticonvulsant properties of benzodiazepines (36, 37) , pharmacological studies using a selective GABA A1 antagonist (38, 39) indicate that the anticonflict (but not the motor impairing) actions of diazepam (11, 40) are mediated via GABA A1 receptors. There are other significant inconsistencies between data obtained in knock-in mice and pharmacological studies using subtype selective pharmacological agents in wild type animals (41). It is not known whether such differences relate to the behavioral assays used, species differences, or a combination of these factors. Furthermore, given both the array of symptoms associated with GAD and the potential for GABA A receptor heterogeneity, ocinaplon may activate multiple GABA A receptor isoforms, including those not examined in the present study, to produce an anxioselective action in the clinic. The present results demonstrate ocinaplon represents both a significant advance in the treatment of generalized anxiety disorder and a unique tool for studying the molecular substrates of anxiety. 
